Next-generation technology at Point of Care

With society reopaened in many countries, non-COVID-19 viruses are potentially circulating again.
The causes and types of respiratory tract infections (RTIs) are wide and can be difficult to discriminate by symptoms alone.
Rapid identification of the underlying cause of respiratory illness can guide appropriate clinical decisions, helping to improve patient outcomes and patient workflows

for more information

 

 

Multiple tests, one Platform

The next-generation high sensitivity microfluidic technology on the LumiraDx Platform contains some of the key assays for respiratory pathogens and biomarkers* on one platform, helping identify and differentiate the underlying cause of respiratory illness and helping inform treatment decisions at the point of care.

 

For more information about the tests

• SARS-CoV-2 & Flu A/B

  An abstract to summarize the performance evaluation of SARS-CoV-2 & Flu A/B

  download
• SARS-CoV-2 Ag

  A clinical performance study of SARS-CoV-2 Antigen Test, published in Infectious Disease Therapy

  Read more
• SARS-CoV-2 Ag Pool

  COVID-19 testing for Icelandic industries – we talk to Arctic Therapeutics

  Watch now
• SARS-CoV-2 Ab

  Evaluation of SARS-CoV-2 Antibody point of care devices in the laboratory and clinical setting

  Read more
• CRP

  Review of CRP point of care testing, published in the BMJ Open Respiratory Research

  Read more